Related Experiment Video
Updated: Oct 31, 2025
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders
Chaojie Zhu1,2,3, Junkai Ma2,3, Zhiheng Ji2,3
1Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Insights
Cell membrane coated nanoparticles (CMCNPs) offer promising biomimetic properties for treating cardiovascular diseases (CVDs). This nanomedicine approach aims to overcome limitations of current diagnostic and therapeutic strategies for CVDs.
Area of Science:
- Biomedical Nanotechnology
- Cardiovascular Medicine
- Materials Science
Background:
- Cardiovascular diseases (CVDs) are the leading global cause of mortality, accounting for 17.9 million deaths annually.
- Atherosclerosis underlies CVDs, manifesting as coronary heart disease, stroke, and peripheral vascular disorders.
- Current treatments face limitations, including contrast agent toxicity and bleeding risks from anti-platelet drugs.
Purpose of the Study:
- To review the advantages of cell membrane coated nanoparticles (CMCNPs) in cardiovascular disease treatment.
- To explore the potential of CMCNPs in enhancing current clinical management strategies for CVDs.
- To highlight the biomimetic properties of CMCNPs for improved therapeutic outcomes.
Main Methods:
- Review of current literature on nanomedicine applications in cardiovascular diseases.
- Focus on cell membrane coated nanoparticles (CMCNPs) and their unique properties.
- Analysis of CMCNPs' potential to overcome existing clinical intervention limitations.
Main Results:
- CMCNPs exhibit biomimetic characteristics beneficial for biomedical applications.
- Membrane coating of nanoparticles aids in evading immune clearance.
- CMCNPs possess versatile cellular and functional mimicry capabilities.
Conclusions:
- Cell membrane coated nanoparticles show significant promise for advancing cardiovascular disease treatment.
- CMCNPs offer a potential solution to limitations associated with current CVD therapies.
- Further research into CMCNPs could optimize nanomedicine's role in cardiovascular care.
Abstract:
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, causing approximately 17.9 million deaths annually, an estimated 31% of all deaths, according to the WHO. CVDs are essentially rooted in atherosclerosis and are clinically classified into coronary heart disease, stroke and peripheral vascular disorders. Current clinical interventions include early diagnosis, the insertion of stents, and long-term preventive therapy. However, clinical diagnostic and therapeutic tools are subject to a number of limitations including, but not limited to, potential toxicity induced by contrast agents and unexpected bleeding caused by anti-platelet drugs. Nanomedicine has achieved great advancements in biomedical area. Among them, cell membrane coated nanoparticles, denoted as CMCNPs, have acquired enormous expectations due to their biomimetic properties. Such membrane coating technology not only helps avoid immune clearance, but also endows nanoparticles with diverse cellular and functional mimicry. In this review, we will describe the superiorities of CMCNPs in treating cardiovascular diseases and their potentials in optimizing current clinical managements.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:27Bioavailability Enhancement: Drug Permeability Enhancement